lunresertib   Click here for help

GtoPdb Ligand ID: 13211

Synonyms: (Rac)-RP-6306
PDB Ligand
Compound class: Synthetic organic
Comment: Lunresertib (RP-6306) is the first lead candidate in the class of protein kinase, membrane associated tyrosine/threonine 1 (PKMYT1) inhibitors to be advanced for clinical evaluation [3]. It is orally bioavailable and selective for PKMYT1, and it is active in appropriate preclinical xenograft models of solid tumours [1]. PKMYT1 is a negative regulator of CDK1 [2], and its inhibition induces activation of CDK1 selectively in CCNE1-overexpressing cells; CCNE1 being a chromosome 19q12 locus that is amplified in multiple tumour types and which is a marker of poor prognosis and/or insensitivity to cytotoxic oncotherapies. As a monotherapy lunresertib induces synthetic lethality in combination with CCNE1 amplification (or alongside inactivating mutations in FBXW7 and PPP2R1A).

Structure note: the INN record for lunresertib does not specify the (S) stereo specification that is declared in the original disclosure of RP-6306's chemical structure [3]. We depict the racaemic mixture with no defined stereo centers.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 104.94
Molecular weight 324.38
XLogP 1.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=C(C(=C1N2C(=C(C3=C2N=C(C)C(=C3)C)C(=O)N)N)C)O
Isomeric SMILES CC1=C(C(=C(C=C1)O)C)N2C(=C(C3=C2N=C(C(=C3)C)C)C(=O)N)N
InChI InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24)
InChI Key ARBRHWRTXPWZGN-UHFFFAOYSA-N
References
1. Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R et al.. (2022)
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Nature, 604 (7907): 749-756. [PMID:35444283]
2. Lee MH, Yang HY. (2001)
Negative regulators of cyclin-dependent kinases and their roles in cancers.
Cell Mol Life Sci, 58 (12-13): 1907-22. [PMID:11766887]
3. Szychowski J, Papp R, Dietrich E, Liu B, Vallée F, Leclaire ME, Fourtounis J, Martino G, Perryman AL, Pau V et al.. (2022)
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
J Med Chem, 65 (15): 10251-10284. [PMID:35880755]